81-49-2Relevant articles and documents
PROCESS OF PREPARING TYROSINE KINASE INHIBITOR
-
Page/Page column 17-18, (2017/03/21)
The invention relates to a process for preparing sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzoate.
Efficient, facile metal free protocols for the bromination of commercially important deactivated aminoanthracene-9,10-diones
Patil, Vilas V.,Gayakwad, Eknath M.,Patel, Khushbu P.,Shankarling, Ganapati S.
supporting information, p. 2608 - 2613 (2017/06/13)
Highly efficient, mild synthetic protocols were developed for the oxidative bromination of deactivated aminoanthracene-9,10-diones by using H2O2-HBr and m-CPBA-HBr in methanolic medium. Both the protocols offer excellent bromine atom economy, good conversion (100%) along with high yield (82–93%) and high purity of desired product. The N-alkylated amines undergo regio-selective bromination to give selective p-bromo product. The commercial availability of all the starting materials, simple reaction procedure and ease of work up, and easily amenable for scale up demonstrated commercial feasibility of both the protocols.
PROCESS FOR PREPARING SUBSTITUTED 9,10-DIOXO-9,10-DIOXO-9,10-DIHYDROANTHRECENES AND 6H-ANTHRA(1,9-CD)ISOXAZOL-6-ONES
-
Page/Page column 21; 22, (2017/10/18)
The disclosure provides processes of preparing compounds of Formula (I) and Formula (IV), their salts, and intermediates thereof, wherein R1, R2, R3, and R7 are defined as set forth in the specification.
SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT
-
Page/Page column 53-55, (2017/03/08)
The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.
Syntheses of 2-substituted 1-amino-4-bromoanthraquinones (bromaminic acid analogues) - Precursors for dyes and drugs
Malik, Enas M.,Baqi, Younis,Müller, Christa E.
supporting information, p. 2326 - 2333 (2016/02/12)
Anthraquinone (AQ) derivatives play a prominent role in medicine and also in textile industry. Bromaminic acid (1-amino-4-bromoanthraquinone-2-sulfonic acid) is an important precursor for obtaining dyes as well as biologically active compounds through the replacement of the C4-bromo substituent with different (ar)alkylamino residues. Here we report methods for the synthesis of bromaminic acid analogues bearing different substituents at the 2-position of the anthraquinone core. 1-Aminoanthraquinone was converted to its 2-hydroxymethyl-substituted derivative which, under different reaction conditions, yielded the corresponding carbaldehyde, carboxylic acid, and nitrile derivatives. The latter was further reacted to obtain 1-amino-2-tetrazolylanthraquinone. Subsequent bromination using bromine in DMF led to the corresponding bromaminic acid derivatives in excellent isolated yields (>90%) and high purities. Alternatively, 1-amino-4-bromo-2-hydroxymethylanthraquinone could be directly converted to the desired 2-substituted bromaminic acid analogues in high yields (85-100%). We additionally report the preparation of bromaminic acid sodium salt and 1-amino-2,4-dibromoanthraquinone directly from 1-aminoanthraquinone in excellent yields (94-100%) and high purities. The synthesized brominated AQs are valuable precursors for the preparation of AQ drugs and dyes.
COMPOSITIONS OF COMPOUNDS AND USES THEREOF
-
Paragraph 0199; 0200, (2015/09/22)
The present disclosure relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same. The disclosure further concerns the use of such compounds in the treatment and/or prevention of certain types of cancers, pain, inflammation, restenosis, atherosclerosis, psoriasis, thrombosis, Alzheimer's, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.
POLYMERIZABLE DICHROIC DYES
-
Page/Page column 8, (2015/12/08)
The present invention relates to new dichroic dyes, their composition with slave materials and their use for a dichroic polymer network, a dichroic liquid crystalline polymer film (LCP film) or a dichroic liquid crystalline polymer gel, which for instance find application as electro- optical or optical devices.
Nonanebis(peroxoic acid): A stable peracid for oxidative bromination of aminoanthracene-9,10-dione
Patil, Vilas Venunath,Shankarling, Ganapati Subray
, p. 921 - 928 (2014/05/20)
A new protocol for the oxidative bromination of aminoanthracene-9,10-dione, which is highly deactivated towards the electrophilic substitution is investigated. The peracid, nonanebis(peroxoic acid), possesses advantages such as better stability at room temperature, it is easy to prepare and non-shock sensitiv as compared to the conventional peracids. The present protocol has a broad scope for the bromination of various substituted and unsubstituted aminoanthracene-9,10-diones.
CRYSTALLINE FORMS OF TRYOSINE KINASE INHIBITORS AND THEIR SALTS
-
Paragraph 0045, (2014/09/30)
The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.
Anthroneamine based chromofluorogenic probes for Hg2+ detection in aqueous solution
Kumar, Ashwani,Kumar, Subodh
body text, p. 2030 - 2034 (2012/07/17)
Anthroneamine derivatives 1-3 (H2O:DMSO; 9:1, HEPES buffer, pH 7.0 ± 0.1) undergo highly selective fluorescence quenching with Hg 2+. The observed linear fluorescence intensity change allows the quantitative detection of Hg2+ between 200 nM/40 ppb - 12 μM/2.4 ppm even in the presence of interfering metal ions viz. Na+, K +, Mg2+, Ca2+, Ba2+, Cr 3+, Fe2+, Co2+, Ni2+, Cu 2+, Zn2+, Ag+, Cd2+, Pb 2+. Probes 1-3 and their Hg2+ complexes also show the broad pH resistance for their practical applicability.